Copyright © 2007, European Society of Cardiology
TGF-β signaling in vascular fibrosis
Vascular and Renal Research Laboratory, Fundación Jiménez Diaz, Universidad Autónoma Madrid, Avda. Reyes Católicos, 2, 28040 Madrid, Spain
* Corresponding author. Tel.: +34 1 5504800x3168; fax: +34 1 5494764. Email address: mruizo{at}fjd.es
Transforming growth factor-β (TGF-β) participates in the pathogenesis of multiple cardiovascular diseases, including hypertension, restenosis, atherosclerosis, cardiac hypertrophy and heart failure. TGF-β exerts pleiotropic effects on cardiovascular cells, regulating cell growth, fibrosis and inflammation. TGF-β has long been believed to be the most important extracellular matrix regulator. We review the complex mechanisms involved in TGF-β-mediated vascular fibrosis that includes the Smad signaling pathway, activation of protein kinases and crosstalk between these pathways. TGF-β blockade diminishes fibrosis in experimental models, however better antifibrotic targets are needed for an effective therapy in human fibrotic diseases. A good candidate is connective tissue growth factor (CTGF), a downstream mediator of TGF-β-induced fibrosis. Among the different factors involved in vascular fibrosis, Angiotensin II (AngII) has special interest. AngII can activate the Smad pathway independent of TGF-β and shares with TGF-β many intracellular signals implicated in fibrosis. Blockers of AngII have demonstrated beneficial effects on many cardiovascular diseases and are now one of the best options to block TGF-β fibrotic responses. A better knowledge of the intracellular signals of TGF-β can provide novel therapeutic approaches for fibrotic diseases.
KEYWORDS Angiotensin; Fibrosis; Smooth muscle; MAPK kinases; Signal transduction
Time for primary review 26 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. Popovic, E. A. Bridenbaugh, J. D. Neiger, J.-J. Hu, M. Vannucci, Q. Mo, J. Trzeciakowski, M. W. Miller, T. W. Fossum, J. D. Humphrey, et al. Transforming growth factor-{beta} signaling in hypertensive remodeling of porcine aorta Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2044 - H2053. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sawada, H. Itoh, K. Miyashita, H. Tsujimoto, M. Sone, K. Yamahara, Z. P. Arany, F. Hofmann, and K. Nakao Cyclic GMP Kinase and RhoA Ser188 Phosphorylation Integrate Pro- and Antifibrotic Signals in Blood Vessels Mol. Cell. Biol., November 15, 2009; 29(22): 6018 - 6032. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Divakaran, J. Adrogue, M. Ishiyama, M. L. Entman, S. Haudek, N. Sivasubramanian, and D. L. Mann Adaptive and Maladptive Effects of SMAD3 Signaling in the Adult Heart After Hemodynamic Pressure Overloading Circ Heart Fail, November 1, 2009; 2(6): 633 - 642. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. An, H. J. Kim, K.-H. Cho, and N. D. Vaziri Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney Am J Physiol Renal Physiol, October 1, 2009; 297(4): F895 - F903. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Jiang, M. Tao, K. A. Omalley, D. Wang, C. K. Ozaki, and S. A. Berceli Established neointimal hyperplasia in vein grafts expands via TGF-{beta}-mediated progressive fibrosis Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1200 - H1207. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Nishimura Integrin-Mediated Transforming Growth Factor-{beta} Activation, a Potential Therapeutic Target in Fibrogenic Disorders Am. J. Pathol., October 1, 2009; 175(4): 1362 - 1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Hausenloy and D. M. Yellon Cardioprotective growth factors Cardiovasc Res, July 15, 2009; 83(2): 179 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Chen, Z. Huang, L. Wang, Y. Wang, F. Wu, S. Meng, and C. Wang MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages Cardiovasc Res, July 1, 2009; 83(1): 131 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Kelly, A. J. Edgley, Y. Zhang, K. Thai, S. M. Tan, A. J. Cox, A. Advani, K. A. Connelly, C. I. Whiteside, and R. E. Gilbert Protein kinase C-{beta} inhibition attenuates the progression of nephropathy in non-diabetic kidney disease Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1782 - 1790. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Sanders Dietary Salt Intake, Salt Sensitivity, and Cardiovascular Health Hypertension, March 1, 2009; 53(3): 442 - 445. [Full Text] [PDF] |
||||
![]() |
S. V. Chatzikyriakou, D. N. Tziakas, G. K. Chalikias, D. A. Stakos, A. K. Thomaidi, K. Mitrousi, A. E. Lantzouraki, S. Kotsiou, E. Maltezos, and H. Boudoulas Serum levels of collagen type-I degradation markers are associated with vascular stiffness in chronic heart failure patients Eur J Heart Fail, December 1, 2008; 10(12): 1181 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Piper, D. Garcia-Dorado, and E. A. Martinson Monitoring the success of articles: a look back and a look ahead Cardiovasc Res, December 1, 2008; 80(3): 321 - 323. [Full Text] [PDF] |
||||
![]() |
C.-X. Lin, N.-E. Rhaleb, X.-P. Yang, T.-D. Liao, M. A. D'Ambrosio, and O. A. Carretero Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1253 - H1261. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-Z. Ying, K. Aaron, and P. W. Sanders Mechanism of dietary salt-mediated increase in intravascular production of TGF-{beta}1 Am J Physiol Renal Physiol, August 1, 2008; 295(2): F406 - F414. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Aubin, C. Lajoie, R. Clement, H. Gosselin, A. Calderone, and L. P. Perrault Female Rats Fed a High-Fat Diet Were Associated with Vascular Dysfunction and Cardiac Fibrosis in the Absence of Overt Obesity and Hyperlipidemia: Therapeutic Potential of Resveratrol J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 961 - 968. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kisseleva and D. A. Brenner Fibrogenesis of Parenchymal Organs Proceedings of the ATS, April 15, 2008; 5(3): 338 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fu, M. J. Corbley, L. Sun, J. E. Friedman, F. Shan, J. L. Papadatos, D. Costa, F. Lutterodt, H. Sweigard, S. Bowes, et al. SM16, an Orally Active TGF-{beta} Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 665 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N Artaza, R. Singh, M. G Ferrini, M. Braga, J. Tsao, and N. F Gonzalez-Cadavid Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/2 cells without affecting their differentiation into myofibroblasts J. Endocrinol., February 1, 2008; 196(2): 235 - 249. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kisseleva and D. A. Brenner Mechanisms of Fibrogenesis Experimental Biology and Medicine, February 1, 2008; 233(2): 109 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yagi, K.-i. Aihara, Y. Ikeda, Y. Sumitomo, S. Yoshida, T. Ise, T. Iwase, K. Ishikawa, H. Azuma, M. Akaike, et al. Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency Circ. Res., January 4, 2008; 102(1): 68 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ruperez, R. Rodrigues-Diez, L. M. Blanco-Colio, E. Sanchez-Lopez, J. Rodriguez-Vita, V. Esteban, G. Carvajal, J. J. Plaza, J. Egido, and M. Ruiz-Ortega HMG-CoA Reductase Inhibitors Decrease Angiotensin II-Induced Vascular Fibrosis: Role of RhoA/ROCK and MAPK Pathways Hypertension, August 1, 2007; 50(2): 377 - 383. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Mehta and H. Attramadal The TGF{beta} superfamily in cardiovascular biology Cardiovasc Res, May 1, 2007; 74(2): 181 - 183. [Full Text] [PDF] |
||||














